Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndrome Treated with Hypomethylating Agents: A SEER-Medicare Analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.1876714
Abstract: AIMS To describe healthcare resource utilization (HRU) and costs in patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA) based on HMA-treatment response. MATERIALS AND METHODS SEER-Medicare data (01/2006-12/2016) were used to identify adults… read more here.
Keywords: treatment success; treatment failure; treatment; hma treatment ... See more keywords
Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7033
Abstract: 7033Background: Outcomes for patients (pts) with RR-AML are poor, with limited treatment options. Salvage HMA therapy has been explored for RR-AML but is often considered palliative. We examined re... read more here.
Keywords: treatment bridge; hypomethylating agent; treatment; hma treatment ... See more keywords